Enhancing Efficacy of Immunotherapy and Chemo-Therapy Treatments

Tech ID: 24838 / UC Case 2015-268-0

ABSTRACT

Researchers at the University of California, Davis campus have discovered the use of certain compounds as immunomodulators for enhancing the efficacy of immunotherapy and chemoradiotherapy.

FULL DESCRIPTION

Human cancers frequently express tumor associated antigens (TAA) that are altered forms of self-proteins or epitopes with limited or no expression in normal cells. The identification of TAAs in cancer has made the development of cancer immunotherapies an attractive area of pharmaceutical research. The efficacy of chemotherapy is known to be affected by inflammation, which is also a target for novel therapeutic strategies. Agents that regulate the inflammatory microenvironment created by tumorgenesis and chemotherapy may improve the response to both cancer immunotherapies and chemo-radiotherapy through immunomodulation.

UC Davis researchers have discovered the use of previously known compounds for immunomodulation of chemo-radiotherapy and immunotherapy.

APPLICATIONS

Cancer therapy

FEATURES/BENEFITS

Improved Efficacy for Immunotherapy and Chemotherapy

PATENT STATUS

Country	Type	Number	Dated	Case
United States Of America	Issued Patent	10,154,970	12/18/2018	2015-268

CONTACT

Raj Gururajan
rgururajan@ucdavis.edu
tel: 530-754-7637.

INVENTORS

- DeGregorio, Michael W.

OTHER INFORMATION

CATEGORIZED AS

- **Medical**
  - Disease: Cancer
  - New Chemical Entities, Drug Leads
  - Therapeutics

RELATED CASES

2015-268-0

University of California, Davis

Technology Transfer Office

1 Shields Avenue, Mrak Hall 4th Floor,

Davis,CA 95616

Tel:

530.754.8649

techtransfer@ucdavis.edu

https://research.ucdavis.edu/technology-transfer/

Fax:

530.754.7620